Bispecific T-cell engagers developed for blood cancers are being repurposed to eliminate pathogenic B cells and plasma cells in severe autoimmune disease, potentially offering CAR-T-like depth without individualized cell manufacturing.
Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.
Find out how Voro Therapeutics and Alloy Therapeutics aim to advance safer masked T-cell engager cancer therapies.
Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.
Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.